pdufa.bio
Home › CRL letters › July 2026

FDA complete response letters, July 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 4 letters dated July 2026 (openFDA, last updated 2026-08-26). Of the 14 FDA decisions on PDUFA goal dates pdufa.bio tracked in July 2026, 0 were Complete Response Letters.

Released by the FDA, dated July 2026 · 4

Letter dateCompanyApplicationopenFDA statusLetter
2026-07-21Apiject Systems Corp.NDA 219107Unapprovedletter (PDF)
2026-07-09Jiangsu Hengrui Pharmaceuticals Co., Ltd.BLA 761308Unapprovedletter (PDF)
2026-07-09Elevar Therapeutics Inc.NDA 216586Unapprovedletter (PDF)
2026-07-02Ascelia Pharma ABNDA 220544Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 0

None: the 14 tracked decisions this month were approvals.
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← June 2026 · August 2026 → · all released letters · every CRL decision we tracked